We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Vertex Pharmaceuticals (VRTX - Free Report) closed at $514.70, marking a +2.54% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.28% for the day. On the other hand, the Dow registered a gain of 1.02%, and the technology-centric Nasdaq decreased by 0.02%.
Heading into today, shares of the drugmaker had lost 1.72% over the past month, lagging the Medical sector's gain of 1.01% and the S&P 500's gain of 0.67%.
The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. The company's earnings report is expected on November 2, 2026. The company is forecasted to report an EPS of $4.92, showcasing a 2.5% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $3.4 billion, indicating a 10.57% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $18.92 per share and a revenue of $13.22 billion, signifying shifts of +2.83% and +10.14%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Vertex Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.65% higher. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 26.53. This denotes a premium relative to the industry average Forward P/E of 25.
We can also see that VRTX currently has a PEG ratio of 2.13. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.77 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 98, finds itself in the top 40% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX - Free Report) closed at $514.70, marking a +2.54% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.28% for the day. On the other hand, the Dow registered a gain of 1.02%, and the technology-centric Nasdaq decreased by 0.02%.
Heading into today, shares of the drugmaker had lost 1.72% over the past month, lagging the Medical sector's gain of 1.01% and the S&P 500's gain of 0.67%.
The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. The company's earnings report is expected on November 2, 2026. The company is forecasted to report an EPS of $4.92, showcasing a 2.5% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $3.4 billion, indicating a 10.57% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $18.92 per share and a revenue of $13.22 billion, signifying shifts of +2.83% and +10.14%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Vertex Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.65% higher. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 26.53. This denotes a premium relative to the industry average Forward P/E of 25.
We can also see that VRTX currently has a PEG ratio of 2.13. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.77 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 98, finds itself in the top 40% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.